Novo Nordisk's EUR 1.17 Billion Bet on Longer-Lasting Shots Fails to Move the Needle
Published on 09/26/2026 at 05:10 | Editorial boerse-global.de
Novo Nordisk has locked up worldwide exclusive rights to Nanexa's PharmaShell drug-delivery platform, a deal that could reshape how frequently patients inject the company's next generation of peptide medicines. The Swedish specialty firm's inorganic particle-coating technology is designed to stretch dosing intervals from once weekly to once monthly — or even once a quarter — across as many as five development programs spanning obesity, type 2 diabetes and cardiometabolic disease.
The financial architecture of the agreement reaches up to EUR 1.17 billion, with EUR 615 million earmarked for upfront payments and development and regulatory milestones. The remainder hinges on future sales thresholds, supplemented by low single-digit royalty rates on global net revenues. Novo Nordisk will shoulder global clinical development and commercialization on its own.
A Familiar Playbook, Scaled Up
The Nanexa tie-up is the latest in a string of external partnerships through which the Danish drugmaker is importing expertise rather than building it in-house. Earlier this month, Novo Nordisk struck a licensing deal with Orbis Medicines covering oral cardiometabolic therapies, with milestone payments and royalties reaching up to USD 1.4 billion. Kallyope also features among recent collaborators.
Henrik Hallengren Laustsen, an analyst at Jyske Bank, said the partnership underscores management's determination to open new growth avenues, though he cautioned that by the standards of a company Novo Nordisk's size, the transaction is a relatively modest one.
Extending dosing intervals has become a critical battleground in metabolic medicine, where adherence rates often determine commercial success. Eli Lilly is pursuing comparable concepts, including through a partnership with Camurus. The pressure to act is amplified by the approaching loss of patent protection on semaglutide, the company's revenue engine, in the early 2030s.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Analysts Trim Targets as the Clock Ticks
Sentiment on the stock remains cautious. On Tuesday, Jefferies cut its price target to DKK 275 from DKK 285 while keeping a "Hold" rating, explicitly citing lingering uncertainty ahead of the semaglutide patent expiry. Deutsche Bank moved in the same direction that day, lowering its target to DKK 245 from DKK 265 and maintaining a "Sell" recommendation. The market, it appears, wants hard evidence that the successor generation can defend the fat margins of the past.
Management has set a goal of bringing more than five blockbuster medicines to market by 2030. By 2035, revenue from the company's own development pipeline is targeted to exceed DKK 150 billion — a figure based on internal, risk-adjusted assumptions that exclude any future acquisitions.
Shares closed Friday at EUR 34.05, a gain of 0.2% on the day, but the stock has shed 23% since the start of the year. In the wake of a weak trading week, the equity showed little reaction to the Nanexa announcement, changing hands at EUR 33.95. Nanexa's own shares jumped sharply in Stockholm once the deal was confirmed. For Novo Nordisk investors, attention now centers on clinical progress rather than deal flow.
CagriSema Data Offers the Bull Case
The optimistic reading of Novo Nordisk's prospects rests largely on late-stage clinical results. In a Phase 3 diabetes trial, the combination therapy CagriSema delivered an estimated average weight reduction of 12.4%, outperforming a 5 mg dose of Eli Lilly's rival tirzepatide on that measure. A separate late-stage obesity study showed 21% weight loss at a 1.0 mg dose versus placebo.
Running alongside those results is a strategic pivot in how medicines are delivered. CEO Mike Doustdar told Reuters on Tuesday that oral obesity treatments could capture as much as half the global market for weight-loss drugs by 2030. He argued that rivals' heavy focus on injectables could hand Novo Nordisk a structural advantage. Should the company establish leadership in both oral formulations and long-acting injections, the payoff for its earnings profile could be substantial. Management has also signaled that its balance sheet can absorb larger acquisitions, leaving room for further dealmaking.
Pricing Pressure and Lilly's Shadow
Against that upbeat scenario stand real operational hazards. The analyst downgrades reflect concrete doubts about future pricing assumptions and the durability of the pipeline. Development costs are climbing in step with the billion-euro licensing commitments, while competition with Eli Lilly is intensifying.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
If regulators demand delays on new drug combinations, or if successor products fail to command the prices management anticipates, the medium-term revenue plan comes under strain. The shift toward tablet formulations carries internal risks of its own: building manufacturing and supply chains for oral medicines demands heavy investment and ties up capital, even as generic manufacturers prepare to flood existing markets once semaglutide's protection lapses.
A potential direct listing on the New York Stock Exchange, which would replace the company's existing depositary receipts, remains on the table according to Doustdar — but is not being actively pursued. That leaves shareholders without a near-term structural catalyst from a changed US trading presence.
What to Watch
As long as the stock holds its 52-week low of EUR 30.25, the case for a bottoming-out remains intact. A decisive break below that level under sustained selling pressure, however, would threaten a re-rating of the entire medium-term growth premium, as the market would likely price in a sharper revenue decline after semaglutide's patent expires.
The next leg of the story will be written by the five newly licensed PharmaShell programs and by further data on CagriSema's clinical tolerability and efficacy. Over the coming months, investors will be watching closely to see whether management converts its stated openness to larger corporate purchases into action — and whether that is enough to secure the blockbuster ambitions it has set for 2030.
Ad
Novo Nordisk Stock: New Analysis - 26 September
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
